
According to WHO, there are a total of 155 new coronavirus vaccines under development worldwide, of which 23 have entered the clinical trial stage, at least 3 vaccines are currently in Phase 3 clinical trials, and at least 3 vaccines have completed phase 2 trials and are about to enter phase 3 (see the figure below for details).
Agency | Country | Progress |
Sinopharm/Wuhan Institute of Biological Products | China | Phase 3 |
Sinovac R&D | China | Phase 3 |
Oxford/AstraZeneca | UK | Phase 3 |
Sinopharm/Beijing Institute of Biological Products | China | Phase 2 |
Chinese Army's Medical Research Institute/CanSino Biologics | China | Phase 2 |
BioNTech/Pfizer | USA | Phase 2 |
Moderna | USA | Phase 2 |
A Phase 1 study typically studies a small number of people, normally 20-80 persons and focuses on whether a vaccine is safe and induces an immune response.
In Phase 2, the clinical study is expanded to several hundred persons and studies the safety, immunogenicity, recommended dosage, immunization schedule and methods of vaccination of candidate vaccinesA Phase 1 study typically studies a small number of people, normally 20-80 persons and focuses on whether a vaccine is safe and induces an immune response.
In Phase 3, the vaccine is given to thousands of people and the key goal is to evaluate the efficacy and again for safety.
The good news is all the above vaccines are now showing positive results.
The COVID-19 vaccine, as the most effective method to prevent infection with the COVID-19 virus, could be available by year end or early next year. But before getting vaccinated, keep social distancing, wear face mask and wash hands frequently can still be the best ways to protect the public from getting infected.
For government, finding (using rapid test kits) and tracking (using tracking app) could be much helpful in preventing the spread of COVID-19.

More information about Singclean IgG/IgM Test Kit, please find
-
singclean | 2020-07-29
Singclean’s Medical Sodium Hyaluronate Gel for Bone Joint Gained EU MDR CE Certification, Ranking Among First 3 Globally! 协合医疗骨科医用透明质酸钠凝胶成功斩获欧盟MDR CE认证!跻身全球前三!This achievement sets multiple industry records: it is the first MDR CE certificate for hyaluronic acid-based orthopedic products ever issued by DNV worldwide. Singclean Medical has become the first Chinese company to obtain such certification in this category and has successfully ranked among the first 3 companies globally to secure a viscosupplementation MDR CE certificate. This accomplishment underscores Singclean Medical's technological expertise and international competitiveness in the field of orthopedic biomaterials and hyaluronic acid applications. 此次认证创造了多项行业纪录:这是DNV在全球范围内签发的首张透明质酸骨科类MDR CE证书;协合医疗为中国首家获此证书的企业,更成功跻身全球前三。这一成绩,充分彰显了协合医疗在骨科生物医用材料及透明质酸领域的技术积累与国际竞争力。 -
singclean | 2020-07-29
Singclean Medical’s 2nd International Aesthetic Medicine Leadership Summit Concludes Successfully in Shanghai Shanghai, August 27, 2026 – The 2nd International Aesthetic Medicine Leadership Summit, hosted by Singclean Medical, was held at W Shanghai – The Bund, within the IMCAS China Congress venue. Under the theme “Global Vision, Opening a New Chapter,” the summit served as a cross‑border, multi‑disciplinary platform for professional exchange, gathering an impressive lineup of leading physicians and global partners. -
singclean | 2020-07-29
Singclean Medical to Showcase Innovative Aesthetic and Medical Solutions at Dubai Derma 2026 and Medical Fair Asia 2026HANGZHOU, China – Hangzhou Singclean Medical Products Co., Ltd., a leading innovator in absorbable biomaterials and medical aesthetic solutions, has announced its participation in two major international exhibitions in September 2026: Dubai Derma 2026 in the United Arab Emirates and Medical Fair Asia 2026 in Singapore.